( en | de | ru )

 

Disambiguation

From post

копироватьудалитьдобавить публикацию в буфер
Immortal time bias in observational studies of drug effects.

. Pharmacoepidemiology and drug safety, 16 (3): 241-9 (марта 2007)4793<m:linebreak></m:linebreak>LR: 20071115; CI: (c) 2007; JID: 9208369; 0 (Adrenergic beta-Agonists); 0 (Gastrointestinal Agents); CIN: Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):1036. PMID: 18816873; ppublish;<m:linebreak></m:linebreak>Mesures d&#039;associació; Immortal time bias.
DOI: 10.1002/pds.1357

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed.

Joseph Selvaraj Samy

Mohamed Tayiser Mohamed Mousa Samy

Samy Mostafa

Samy Shamy

Samy Gallego

 

Другие публикации лиц с тем же именем

Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies., , , , и . Diabetes care, 39 (3): 486-94 (марта 2016)Critical appraisal; Bias; Observacionals; Diabetis; Oncologia<br/><br/>Bons gràfics de time bias al material suplementari.Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs., , , , и . Pharmacoepidemiology and drug safety, 16 (8): 845-9 (августа 2007)4654<m:linebreak></m:linebreak>LR: 20081121; JID: 9208369; 0 (Central Nervous System Agents); 12794-10-4 (Benzodiazepines); CIN: Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):850-3. PMID: 17636552; ppublish;<m:linebreak></m:linebreak>Mesures d&#039;associació.Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses, , , , , , , , , и 17 other автор(ы). 329 (16): 1376 (2023)Immortal time bias in observational studies of drug effects.. Pharmacoepidemiology and drug safety, 16 (3): 241-9 (марта 2007)4793<m:linebreak></m:linebreak>LR: 20071115; CI: (c) 2007; JID: 9208369; 0 (Adrenergic beta-Agonists); 0 (Gastrointestinal Agents); CIN: Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):1036. PMID: 18816873; ppublish;<m:linebreak></m:linebreak>Mesures d&#039;associació; Immortal time bias.ACE-I and ARBs in early diabetic nephropathy., , , , , , , , , и . Journal of the renin-angiotensin-aldosterone system : JRAAS, (xx 12 2002)The positivity assumption and marginal structural models: the example of warfarin use and risk of bleeding., , и . European journal of epidemiology, 27 (2): 77-83 (февраля 2012)6578<m:linebreak></m:linebreak>JID: 8508062; 2011/03/28 received; 2011/11/23 accepted; 2011/12/08 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de dades; Marginal structural models.Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?. Diabetes care, 41 (1): 6-10 (января 2018)Mesures d'associació; Immortal time bias; Diabetis.Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores., , и . Pharmacoepidemiology and drug safety, 26 (4): 459-468 (апреля 2017)Propensity score; CER; New-user designs; Diabetis.How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias., , , , , и . Pharmacoepidemiology and drug safety, (января 2019)Databases; Anàlisi de dades.Immeasurable time bias in observational studies of drug effects on mortality.. American journal of epidemiology, 168 (3): 329-35 (августа 2008)4452<m:linebreak></m:linebreak>PUBM: Print-Electronic; JID: 7910653; 0 (Anti-Inflammatory Agents); 0 (Glucocorticoids); 2008/05/30 aheadofprint; ppublish;<m:linebreak></m:linebreak>Mesures d&#039;associació.